CNSL
NEUTRALCambridge Nutritional Sciences Grants Options to CEO
The medical diagnostics company has granted share options to its Chief Executive Officer.
Cambridge Nutritional Sciences
2.5500GBX
0.00%
Market Cap
6.07M
Volume
39.88k
24% of avg
P/E Ratio
EPS (TTM)
Beta
1.42
Day Range
2.5000p - 2.6890p
52 Week Range
0.0251p2.5500p4.4830p
2.5500p
CNSL
NEUTRALCambridge Nutritional Sciences Appoints New CEO
The healthcare company has appointed a new Chief Executive Officer to lead the business forward.
CNSL
NEUTRALCambridge Nutritional Sciences Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
CNSL
NEUTRALCambridge Nutritional Sciences Provides Update on Historical Legal Issue
The healthcare company provides an update on a legal matter regarding a former subsidiary that was sold in 2018.
CNSL
NEUTRALCambridge Nutritional Sciences Announces Director Shareholding Change
The healthcare company has disclosed a change in director shareholdings.
CNSL
NEUTRALCambridge Nutritional Sciences Director Increases Shareholding
The medical diagnostics company's Non-Executive Chair has purchased 100,000 shares, increasing their total holding to 0.08% of the issued share capital.
CNSL
NEUTRALCambridge Nutritional Sciences Director Buys Shares
The medical diagnostics company announced a director has purchased a small number of shares, but provided limited additional context.
CNSL
GOODCambridge Nutritional Sciences Settles DHSC Claim
The healthcare company has settled a long-running legal dispute, allowing it to reclassify £2.5m in deferred income as exceptional income.
CNSL
NEUTRALCantor Fitzgerald Europe Increases Stake in Cambridge Nutritional Sciences
Small increase in shareholding by investment firm, no major business impact.
CNSL
NEUTRALSpreadex Increases Stake in Cambridge Nutritional Sciences
Cambridge Nutritional Sciences, a medical diagnostics company focused on food sensitivity testing, has filed a regulatory notification about a change in shareholding, with Spreadex Ltd increasing its stake to over 14%. This is a routine disclosure and does not suggest any immediate changes to the company's business.